Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat
Executive Summary
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
You may also be interested in...
Astellas’ Zolbetuximab Approval Timeline Unclear After Manufacturing Issues Prompt CRL
After a US FDA site inspection raised questions about the contract manufacturer of the potential first-in-class Claudin 18.2 inhibitor that could not be answered by the original January PDUFA date, Astellas will need to refile the application, but has not committed to when that might be.
US CRL For Astellas's Zolbetuximab Over Manufacturing Issues
Astellas has received a US CRL for it's potential first-in-class drug zolbetuximab, after questions over a manufacturing line came up after an FDA site inspection and could not be answered by the original 12 January PDUFA date. The Japanese firm will refile the application after resolving the issues, but the likely revised timeline is not yet clear.
Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.